Hahn Capital Management LLC Decreases Stock Holdings in Labcorp Holdings Inc. $LH

Hahn Capital Management LLC lessened its stake in Labcorp Holdings Inc. (NYSE:LH) by 16.3% in the first quarter, Holdings Channel reports. The firm owned 26,170 shares of the medical research company’s stock after selling 5,109 shares during the quarter. Labcorp accounts for about 4.4% of Hahn Capital Management LLC’s investment portfolio, making the stock its 6th largest position. Hahn Capital Management LLC’s holdings in Labcorp were worth $6,982,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Labcorp during the fourth quarter worth about $26,000. Hilton Head Capital Partners LLC acquired a new position in shares of Labcorp in the 4th quarter valued at approximately $27,000. JPL Wealth Management LLC acquired a new position in shares of Labcorp in the 3rd quarter valued at approximately $28,000. Eagle Bay Advisors LLC bought a new stake in shares of Labcorp during the 4th quarter worth approximately $29,000. Finally, DV Equities LLC bought a new stake in shares of Labcorp during the 4th quarter worth approximately $29,000. Institutional investors own 95.94% of the company’s stock.

Insider Transactions at Labcorp

In other news, CEO Adam H. Schechter sold 5,903 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the completion of the sale, the chief executive officer directly owned 107,234 shares in the company, valued at approximately $27,291,053. This trade represents a 5.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Bryan T. Vaughn sold 234 shares of Labcorp stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $66,968.46. Following the completion of the transaction, the executive vice president directly owned 6,746 shares of the company’s stock, valued at $1,930,637.74. This represents a 3.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 6,991 shares of company stock valued at $1,796,696. Corporate insiders own 0.84% of the company’s stock.

Labcorp Stock Up 0.1%

Shares of NYSE LH opened at $283.63 on Monday. The company’s 50 day moving average price is $266.22 and its 200-day moving average price is $268.01. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. Labcorp Holdings Inc. has a 52-week low of $241.81 and a 52-week high of $293.72. The company has a market capitalization of $23.26 billion, a P/E ratio of 25.12, a price-to-earnings-growth ratio of 1.88 and a beta of 0.89.

Labcorp (NYSE:LH) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $4.09 by $0.16. The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. Labcorp’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company posted $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Equities analysts forecast that Labcorp Holdings Inc. will post 18 earnings per share for the current year.

Labcorp Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Friday, August 28th. Labcorp’s dividend payout ratio (DPR) is presently 25.51%.

Analyst Ratings Changes

Several research analysts have commented on the stock. Evercore restated an “outperform” rating and set a $300.00 price objective on shares of Labcorp in a research report on Wednesday, April 8th. Bank of America raised their target price on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a report on Monday, July 13th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Finally, Robert W. Baird upped their price objective on Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $314.40.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.